An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer

Trial Profile

An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms X-ACT
  • Most Recent Events

    • 07 Jun 2011 Pooled analysis results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Jun 2010 Results of a subgroup analysis by age have been reported at the 12th World Congress on Gastrointestinal Cancer (2010).
    • 15 Jan 2009 Actual end date Mar 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top